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Introduction
The discipline of clinical pharmacology was founded
in the second half of the 20th century. The American phar-
macologist Harry Gold was the first to recognize the need
for new experts in medicine, saying something like the fol-
lowing: “...the special kind of investigators is needed, who
are familiar not only with the techniques and the basics of
laboratory pharmacology, but also with clinical medicine...”
(1). Clinical pharmacologists should use their profound un-
derstanding of the mechanisms of drugs action and pharma-
cokinetics in solving health problems of the patients in the
real life.
However, from its beginnings, clinical pharmacology
has developed differently in the various parts of the world,
mostly being more research-oriented than health care-
oriented (2). In the United States of America, where clinical
pharmacology was born, it has never reached the patients:
recent surveys of the American Society for Clinical Phar-
macology showed that the majority of around 800 clinical
pharmacologists work in the academia, industry, Contract
Research Organisations (CRO), or government. Their main
work area is the drug development process, but not the us-
age of drugs in health care (3). The majority of American
clinical pharmacologists are doctors of medicine and the
rest of them are either pharmacists or doctors in biology (3,
4). On the other hand, clinical pharmacology in Europe fo-
cuses both on research and health care services. One of the
doyens of clinical pharmacology, professor Folke Sjoqvist,
has recently said: “Clinical pharmacology is not only a re-
search discipline, but also a clinical specialty in its own
right with functions in health care that focus on the rational
use of drugs by physicians and patients” (5). Finally, there
are parts of the world where clinical pharmacologists did
not find their place among other specialties or researchers,
and their role remained unclear to others (6).
The role of clinical pharmacology in health care
should be viewed from the standpoint of health care serv-
ices provided to patients, i.e. consumers. The reason for this
is a prosaic one – the majority of Health Insurance Funds
from all over the world pay for the given services (7–10).
Therefore, if clinical pharmacologists want to be the part of
a health care system, they have to offer well-defined serv-
ices, which are needed either by patients, other medical
doctors, or a medical facility management. However, these
three categories of potential users of clinical pharmacolo-
gists’ services have first to become aware of the extent of
the help they could get from clinical pharmacologists. It is
not surprising that well-established Clinical pharmacology
units exist mostly at University hospitals or other state-of-
art medical facilities, where health care and scientific cul-
ture is sufficiently high (6).
What are the most important services clinical pharma-
cologists could offer? It is difficult to determine, and it de-
pends heavily on the local health care needs (2). Highly de-
veloped health care system would need highly sophisticated
services; the less developed one would ask for the basic
help in rationalization of drug utilization. In this article the
scope of possible services is given, using the activities of
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Hospital Center “Kragujevac”, in Kragujevac (DCP-K),
Serbia and Montenegro as an example. The Clinical Hospi-
tal Centre “Kragujevac” is the university hospital with 1200
beds, around 30000 patients annually and the annual budget
of around 12 million euros.
The services offered directly to the patients
Advising patients after clinical evaluation. Within any
health care system, there are patients to whom various drugs
are prescribed by several specialists, who are often not in-
formed properly (or do not care) about the drugs the patient
is already taking. In the majority of the cases, general prac-
titioners are able to synchronize drug therapy for a patient,
but when the problems of a patient are complex, he or she is
referred to a clinical pharmacologist (11). The clinical
pharmacologist then has to take a history and examine a pa-
tient, as well as to study his or her medical documentation,
in order to understand the patient's problems and give the
appropriate advice.
The DCP-K gave 154 such advices to 136 patients in
the first 6 months of the year 2004.
Giving drug information to the patients directly, by
phone, SMS-messages or e-mail. Giving drug information
to the patients or to the public is not a service uniquely of-
fered by clinical pharmacologists. In the majority of
health care facilities, pharmacists who run the units offer
such service, too, probably due to the small number of
clinical pharmacologists available (12). However, when-
ever possible, the drug information units are best led by
pharmacists, and supervised by clinical pharmacologists;
such organization gives the high quantity of services
combined with the high reliability, as we can learn from
the experience of the Department of Clinical Pharmacol-
ogy in the Huddinge Hospital, Stockholm (13). Some-
times, the drug information service is specialized for only
one area, like “anti-doping hot line”, also operating in the
Huddinge Hospital (14).
During the first 6 months of the year 2004, in DCP-K
86 drug informations were given. The majority of the ques-
tions asked by the patients were those concerning adverse
drug reactions, concomitant drug use and the use of drugs
during pregnancy and lactation.
The services offered to the medical doctors
Advising hospital and primary care physicians, if pos-
sible, after clinical evaluation of their patients. Medical
doctors have often to deal with the patients who have com-
plex health problems, and require several drugs which could
interact with each other, so the help of a clinical pharma-
cologist is needed. This help could be offered in the form of
a detailed report with references (15), when a clinical phar-
macologist(s) studies the literature, evaluates published
studies according to the principles of the evidence-based
medicine, and gives advice to the colleagues. A whole team
usually considers the problem, and stores the case data on
the accessable database, which could be used as a reference
for a similar case. Another option is to examine a patient,
give an advice immediately, and make additional literature
search, if needed. This option may be less reliable, but it has
the advantage of the direct contact with a patient, and get-
ting the true impression about his/her case, which could dif-
fer from the impression of a clinician in charge of that pa-
tient.
In DCP-K, 187 advices for 135 patients were given in
the first 6 months of the year 2004. All the advices were
given according to the second option.
Giving drug information to other medical doctors di-
rectly, by phone, SMS-messages or e-mail. The same staff
which usually gives drug information to patients does it to
the colleagues, too (16,17). Actually, the service is similar
to the one for patients, only the information is much more
extensive. Most questions asked by other medical doctors
are in relation with the adverse drug reactions, the choice of
therapy/drug, and the therapy during pregnancy or breast
feeding (18). Some studies have shown that over 70% of the
colleagues consider such services important for their prac-
tice (15).
In DCP-K, 129 items of drug information were given
to clinicians for the first 6 months of the year 2004. Around
80% of the items were about the choice of a drug.
Reporting adverse drug reactions. For the majority of
developed countries, the rate of spontaneous reporting of
adverse drug reactions (ADR) is at the satisfactory level
(more than 250/1000000 inhabitants); however, the same is
not true for undeveloped or developing countries, or coun-
tries in socio-economic transition, like Serbia & Montene-
gro. Clinical pharmacologists should run the Regional Cen-
ters for adverse drug reactions, but they should also work
on ADR reporting the rate increasement. The colleagues
who suspect an ADR should be able to call a clinical phar-
macologist, who will evaluate the causality of suspected
ADR and help with its reporting. Availability of such a
service makes the reporting easier for a busy clinician, and
also increases the reporting rate significantly (19).
After offering such a service in DCP-K, the reporting
rate of ADR in the hospital increased from 10/year to
40/year.
Therapeutic drug monitoring is one of the most im-
portant services that a clinical pharmacologist can offer.
The measurements of drug concentrations in serum are done
in the hospital biochemical laboratories, but the interpreta-
tion of the measured values is reserved for a clinical phar-
macologist (20). Accurate dose titration could only be made
if all the factors influencing pharmacokinetics of a drug are
taken into account; and only clinical pharmacologists have
sufficient knowledge and the skills to do so.
In DCP-K, the concentrations of both antiepileptics
and antibiotics are measured in serum. The request from a
clinician for the therapeutic drug monitoring first has to be
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urement, the result is followed by the comment of a clinical
pharmacologist. In the first 6 months of the year 2004, 147
patients underwent the therapeutic drug monitoring.
Design of post-marketing studies. Post-marketing drug
studies are often initiated by either medical doctors or
pharmaceutical companies, with various purposes. Accord-
ing to the existing regulations, such studies do not need an
approval of a drug agency, but only a notification. It is only
a clinical pharmacologist who is able to make an appropri-
ate design of such studies, and ensure an ethical verifica-
tion. However, clinicians can hardly expect from clinical
pharmacologists in pharmaceutical companies to make the
design for them – this would simply cost too much; but
clinical pharmacologists working in a health care facility
can offer such a service within the cost limits set by health
insurance funds.
During the first 6 months of the year 2004, the clinical
pharmacologists from DCP-K designed 1 post-marketing
case-control study.
Providing continuing medical education. Continuing
medical education (CME) has become obligatory for each
practicing physician in the majority of the countries. Health
care facilities, especially those of tertiary care, which have a
competent staff could also provide CME (21). Clinical
pharmacologists could offer courses in rational pharmaco-
therapy, which could satisfy both primary and secondary
care physicians. The DCP-K has held two CME courses in
the first half of the year 2004.
The services offered to the management
Serving in Drugs and Therapeutics Committee (DTC)
of a hospital. The DTC is a body through which clinical
pharmacologists may influence drug prescribing in a hospi-
tal. It combines the local guidelines and drug lists develop-
ment, and through it clinical pharmacologists have both
time and an opportunity to actively create the drug policy of
a hospital (22). Unfortunately, due to the lack of clinical
pharmacologists in practice, more than half of the DTCs are
chaired by pharmacists, who, although knowledgeable, lack
the skills of physicians (12).
A clinical pharmacologist has chaired the DTC in the
Clinical Hospital Center “Kragujevac” since its establish-
ment in 1999. A total of 63 local guidelines and three ver-
sions of local drug formulary were produced as a result of
the DTC activity.
Pre-dispensing control of expensive drug prescribing.
Duo to insufficient training in clinical pharmacology at
medical schools and postgraduate education in the majority
of countries (23), it becomes necessary to impose control on
prescribing of expensive drugs. Drug utilization and cost
analysis in the Clinical Hospital Center “Kragujevac” has
shown that only 1 drug (antibiotic ceftriaxone) consumes
around 15% of the drug budget (24)! By imposing pre-
dispensing control on prescribing in the Clinical Hospital
Center “Kragujevac” by a clinical pharmacologist, the con-
sumption of expensive drugs was decreased by 30% in the
year 2003. This service performed 4150 pre-dispensing
chart controls during the year 2003. The prescriptions were
changed in 21% of the cases, but only after the consensus
reached with a prescribing physician.
Periodic auditing of prescribing practice in the hos-
pital. In order to test whether prescribers follow the local
guidelines and the treatment standards, clinical pharma-
cologists should prepare and conduct the audits periodi-
cally. This role of clinical pharmacologists was identified
indirectly by the American College of Clinical Pharmacol-
ogy, which stated that “a clinical pharmacologist should
serve as an ombudsman in all the hospitals to track possible
medication errors and to educate the medical and nursing
staffs on how to mitigate such errors” (25). The audits are
the only way to spot the irrational or erroneous behavior of
prescribers, and to have the basis for planning the corrective
actions (26). It is important to perform auditing according to
the internationally agreed methodology (27).
The clinical pharmacologists from DCP-K perform on
average, 1–2 audits of prescribing practice in the Clinical
Hospital Center “Kragujevac” per year.
Ninety percent drug utilization analysis. Analysis of
drug utilization focusing on the number of drugs constitut-
ing 90% of the volume (DU 90%) is very useful for reveal-
ing prescribing profiles in a health care facility (28). The
DCP-K follows drug utilization in the Clinical Hospital
Center “Kragujevac” according to the WHO methodology
(expressed in the number of defined daily doses per 1000
patient-days) from the year 1997, and with the emphasis on
the utilization of 90% of the volume from the year 2003.
The management of the hospital uses these data for the basis
of the corrective actions (e.g. initiating an audit), if the drug
utilization pattern does not follow the agreed local guide-
lines, as well as for planning drug purchase.
Preparation of a hospital’s drug formulary and drug
procurement list. Although a drug formulary of a hospital is
negotiated and accepted by its DTC, someone has to prepare
the first draft of the list. This is the unique responsibility of a
clinical pharmacologist and in DCP-K this process is repeated
each year. As noted by Feely: “Clinical pharmacologists are
uniquely positioned to determine the cost benefit and utility of
modern therapy and give impartial advice on safe, effective
and economic patient care” (29). Besides the preparation of
the draft, clinical pharmacologists participate actively in the
process of the formulary negotiation.
Starting from a drug formulary, clinical pharmacolo-
gists of DCP-K prepare the drug procurement list draft, too.
Then they negotiate the draft with all the relevant clinicians,
and estimate the necessary drug quantities based on drug
utilization data. Finally, the draft is discussed and agreed
with the chief hospital pharmacist, and handed over to the
procurement committee (30). Participation of a clinical
pharmacologist in this process is important, since no other
expert profile is competent enough to negotiate the drug
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Serving in local Ethics Committee. The Ethics Com-
mittee of a health care facility is necessary for reviewing of
and deciding on the proposals for clinical trials. It should be
organized and it should function according to the interna-
tionally agreed standards, set by WHO (31). Clinical phar-
macologists are familiar with the standards, and educated
enough to discuss the therapeutic options in all the clinical
areas. The president of the Ethics Committee of the Clinical
Hospital Center “Kragujevac” (established in 1997) is a
clinical pharmacologist.
Conclusion
The services mentioned above are the direct response
of clinical pharmacologists to the needs of patients, medical
doctors and hospital management. However, if clinical
pharmacologists are not available, clinical pharmacists take
over these services, as observed in the USA (32, 33).
Whether this is acceptable or not, remains to be seen, al-
though some studies have demonstrated that “system using
pharmacists as independent practitioners to promote pri-
mary care has achieved high-quality and cost-effective pa-
tient care” (32, 34, 35). What clinical pharmacology as a
discipline should perform, are the well-designed studies
which would investigate the impact of services of clinical
pharmacologists to prescribing and health care in general.
This is the only way to exactly define the position of clini-
cal pharmacology in health care system and clinical phar-
macologists from all over the world should be encouraged
to conduct such studies.
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